OmniAb, Inc. Common Stock (OABI) Stock Price Today & Analysis
This article provides an analysis of OmniAb, Inc. (OABI) stock, including its current price, fundamental financials, and corporate information. It details how to buy OABI stock on the Gotrade app, explains that OABI does not currently pay dividends, and offers guidance on evaluating if the stock is expensive or cheap. OmniAb Inc. licenses discovery research technology for next-generation therapeutics, utilizing its OmniAb platform and "Biological Intelligence" to create optimized antibody candidates.
OmniAb, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-05-11
OmniAb, Inc. (NASDAQ:OABI) released its Q1 2026 earnings, reporting an EPS of -$0.06, which beat estimates by $0.04. The company's revenue reached $14.43 million, significantly surpassing expectations by $8.83 million and representing a substantial 247.30% year-over-year increase. This article presents the slide deck from their Q1 earnings call.
Number of shareholders of OmniAb, Inc. – NASDAQ:OABIW
This article provides financial information for OmniAb, Inc. (NASDAQ: OABIW), focusing on its number of shareholders. It appears to be a stub or data-focused page from TradingView, presenting a barebones overview with copyright and product information. The core content is the heading "Number of shareholders of OmniAb, Inc." followed by "Period Value Change Change %," suggesting that the actual data points would be displayed below this structure.
OmniAb (OABI) FY 2025 Loss Of US$64.8m Keeps Profitability Narrative Under Pressure
OmniAb (OABI) reported a FY 2025 net loss of US$64.8 million, with a fourth-quarter revenue of US$8.4 million and a basic EPS loss of US$0.11. The company's profitability is under scrutiny, with sustained losses and forecasts predicting unprofitability for at least the next three years, leading to concerns about potential shareholder dilution, despite a forecasted 30.8% annual revenue growth and a strong partner ecosystem. The stock trades at a high P/S ratio of 11.4x, significantly above its DCF fair value of US$5.21 and analyst target of US$7.33, creating a valuation tension between growth potential and ongoing losses.
OmniAb, Inc. (NASDAQ:OABI) Q1 2026 Earnings Call Transcript
OmniAb, Inc. (NASDAQ: OABI) reported strong Q1 2026 results, beating earnings expectations with a reported EPS of $-0.06 against an expected $-0.1. The company saw a significant increase in revenue, primarily driven by milestone achievements from partner programs advancing in clinical stages. OmniAb also highlighted its innovative technologies like OmniUltra and OmnidAb, which are attracting new partners and expanding its market reach, leading to a revised and increased full-year revenue outlook.
OmniAb, Inc. (OABI) reports Q1 loss, tops revenue estimates
OmniAb, Inc. (OABI) reported a diluted loss per share of $0.06 for Q1, which was narrower than the Zacks Consensus Estimate of a $0.09 loss. The company also exceeded revenue expectations, posting $27.9 million compared to the consensus estimate of $27.01 million. Despite a year-over-year revenue decline, these results indicate a stronger-than-anticipated financial performance for the quarter.
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Announces Target Price $7
Craig-Hallum analyst Matt Hewitt has reiterated a "buy" rating for OmniAb (OABI.US) and set a target price of $7. According to TipRanks data, the analyst has a 38.4% success rate and an average return of -4.3% over the past year. This information is provided for informational purposes and is not an investment recommendation.
OmniAb, Inc. (OABI) reports Q1 loss, tops revenue estimates
OmniAb, Inc. (OABI) reported a first-quarter loss that was wider than anticipated, but its revenue surpassed Wall Street expectations. The company posted a loss of 12 cents per share on revenue of $29.7 million, exceeding analyst forecasts of an 8-cent loss and $28.3 million in revenue.
OmniAb’s Q1 2026 Revenue Rises to $25.3 Million, Net Loss Decreases
OmniAb reported a significant financial improvement in Q1 2026, with revenue increasing by 15% to $25.3 million from $22 million in Q1 2025. Concurrently, the company's net loss decreased to $12.9 million, a substantial improvement from the $20.1 million loss in the prior year's first quarter. These results highlight OmniAb's operational growth and progress.
OmniAb Q1 Earnings Call Highlights
OmniAb (OABI) reported strong Q1 2026 results, driven by progress in its partner pipeline, leading to increased milestone revenue. The company highlighted advancements in clinical programs, including several proprietary technologies entering later-stage development, as well as new technology innovations like OmniUltra. Financial results showed a significant increase in revenue and a narrower net loss year-over-year, leading OmniAb to raise its full-year 2026 revenue guidance.
OmniAb (OABI) Q1 2026 Earnings Transcript
OmniAb (OABI) reported a strong Q1 2026, with total revenue reaching $14.4 million, significantly up from $4.2 million, primarily due to increased milestone revenue from partner clinical program advancements. The company raised its full-year 2026 revenue guidance to $28 million to $33 million, driven by an unanticipated partner milestone, while maintaining unchanged cash operating expense guidance at $50 million to $55 million. OmniAb highlighted the traction of its novel technologies, OmniUltra and OmnidAb, and the growing interest in its xPloration platform, alongside a robust pipeline of over 400 active programs and 32 clinical programs.
OmniAb Q1 Earnings Call Highlights
OmniAb (NASDAQ: OABI) reported a strong first quarter for 2026, driven by significant progress in its partner pipeline and associated milestone revenues. The company ended the quarter with 32 active clinical programs, saw two OmniAb-derived programs enter Phase I human testing, and highlighted several advancements, including an antibody moving from Phase I to Phase III development for multiple myeloma. OmniAb also emphasized its innovative technology, including the newly launched OmniUltra platform, and raised its full-year 2026 revenue outlook to $28 million to $33 million based on Q1 performance.
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $3
TD Cowen has reiterated its Buy rating on OmniAb (OABI.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.
OmniAb (OABI) Q1 2026 revenue surges 247% while net loss shrinks
OmniAb (OABI) reported a significant increase in Q1 2026 revenue, surging 247% to $14.4 million, primarily driven by a $10.0 million increase in license and milestone revenue. While the company remains unprofitable, its net loss narrowed substantially to $7.7 million from $18.2 million in Q1 2025 due to revenue growth and lower operating expenses. OmniAb continues to expand its antibody discovery platform, boasting 107 active partners and 409 active programs, with sufficient cash reserves to fund operations for at least the next 12 months.
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. reported strong first-quarter 2026 financial results, with a significant increase in revenue to $14.4 million and a reduced net loss of $7.7 million. The company raised its full-year 2026 revenue guidance to between $28 million and $33 million, driven by multiple partnered programs advancing into later-stage clinical development, including IMVT-1402 and TEV-'408. OmniAb continues to expand its technology platform with initiatives like OmniUltra™ and its xPloration® partner access program.
OmniAb Reports First Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. reported strong first-quarter 2026 financial results, with revenue significantly increasing to $14.4 million compared to $4.2 million in the prior year, primarily driven by milestone revenue. The company also raised its 2026 financial guidance, anticipating revenue between $28 million and $33 million, and highlighted advances in multiple partner programs into later-stage clinical development, underscoring the value of its technology platform. Key business highlights included progress in IMVT-1402, batoclimab, TEV-'408, and precemtabart tocentecan programs.
OmniAb forecasts $28M-$33M 2026 revenue as partner milestones lift outlook
OmniAb projects its 2026 revenue to be between $28 million and $33 million, driven by anticipated partner milestones. This forecast indicates a significant increase from previous expectations, reflecting strong performance and successful progression of its collaborations. The company's outlook is bolstered by the potential for additional payments tied to the advancement of therapies developed using its technology.
Earnings call transcript: OmniAb Q1 2026 sees revenue surge, stock climbs
OmniAb, Inc. reported a significant 242.9% year-over-year revenue increase to $14.4 million in Q1 2026, leading to a 2.8% stock climb. Despite an InvestingPro analysis suggesting overvaluation, the company improved its net loss significantly and raised its full-year revenue outlook, driven by advancements in partner programs and new technology platforms. The earnings call highlighted the strength of its technology, partner ecosystem, and pipeline, with expectations for continued growth and clinical advancements.
OmniAb, Inc. (OABI) Reports Q1 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) reported a Q1 loss of $0.06 per share, outperforming the Zacks Consensus Estimate of a $0.1 loss, and exceeded revenue estimates with $14.43 million for the quarter ended March 2026. Despite underperforming the market year-to-date, the company holds a favorable Zacks Rank #2 (Buy) due to positive earnings estimate revisions, suggesting potential for future market outperformance. The article also touches on Plus Therapeutics (PSTV) as another stock in the Medical-Drugs industry, which is yet to report Q1 results.
OmniAb to Participate in Two Investor Conferences in November
OmniAb Inc. (OABI) announced its participation in two investor conferences scheduled for November. This news was released via Quantisnow, a real-time market data platform for retail investors. The article also provides recent analyst ratings and SEC filing updates related to OmniAb Inc.
OmniAb Inc expected to post a loss of 10 cents a share - Earnings Preview
OmniAb Inc (OABI) is projected to report a loss of 10 cents per share according to a Reuters earnings preview. This brief article provides financial analysts and investors with an expectation for the company's upcoming earnings report. The information is sourced from Refinitiv.
Insider Buyers At OmniAb Likely Disappointed With 13% Slide
Insiders at OmniAb (NASDAQ:OABI) who invested US$1.28m in the last year are likely disappointed as the stock has slid 13%, reducing their investment to US$1.00m. Despite this, a significant purchase by President Matthew Foehr at a higher price suggests confidence in the company's future. The article notes that OmniAb insiders own 12% of the company, indicating a reasonable alignment with shareholders, but also points out two warning signs that investors should consider.
OmniAb (OABI) Expected to Announce Earnings on Thursday
OmniAb (NASDAQ:OABI) is expected to announce its Q1 2026 earnings after market close on Thursday, May 7th, with analysts forecasting a loss of ($0.10) per share on $5.6850 million in revenue. The company previously missed Q4 earnings and revenue estimates and has seen insider selling, though institutional investors have adjusted their positions. Analysts currently hold a "Hold" consensus rating with a $4.50 price target for the biotechnology firm.
Insider Buyers At OmniAb Likely Disappointed With 13% Slide
Insiders at OmniAb, Inc. (NASDAQ:OABI) who purchased $1.28 million worth of shares at an average price of $1.74 over the past year are likely disappointed by the stock's recent 13% decline, reducing their investment value to $1.00 million. Despite the drop, insider ownership stands at 12%, suggesting some alignment with shareholders. The largest insider purchase was made by President Matthew Foehr for $1 million at $1.85 per share, indicating confidence even at a higher price than current levels.
OmniAb (Nasdaq:OABI) - Stock Analysis
This Simply Wall St analysis for OmniAb (OABI) shows the stock as 81% undervalued with a fair value target of US$7.33, while trading at US$1.39. The company is currently unprofitable but revenue is forecast to grow by 30.82% per year. Recent news includes updated bylaws and 2026 revenue guidance, with analysts nudging price targets slightly higher.
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) announced its participation in three upcoming investor conferences. Management will engage in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, hold one-on-one meetings at the Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, and present a corporate overview at the Jefferies Global Healthcare Conference.
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) announced its participation in three upcoming investor conferences. Management will engage in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6th, hold one-on-one meetings at the Benchmark 6th Annual Healthcare House Call Virtual Investor Conference on May 28th, and present a corporate overview at the Jefferies Global Healthcare Conference from June 2-4.
OmniAb to Participate in Three Upcoming Investor Conferences
OmniAb, Inc. (NASDAQ: OABI) announced its participation in three upcoming investor conferences in May and June. Management will hold a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, conduct one-on-one and small group meetings at the Benchmark 6th Annual Healthcare House Call Virtual Investor Conference, and present a corporate overview and hold meetings at the Jefferies Global Healthcare Conference. The company specializes in licensing discovery research technology for next-generation therapeutics, leveraging its proprietary "Biological Intelligence" platform.
OmniAb to Report First Quarter 2026 Financial Results on May 7
OmniAb, Inc. (NASDAQ: OABI) announced it will release its first quarter 2026 financial results after the market close on Thursday, May 7, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. This call will cover their financial performance for the three months ended March 31, 2026.
OmniAb to Report First Quarter 2026 Financial Results on May 7
OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the first quarter of 2026 on Thursday, May 7, 2026, after the U.S. financial markets close. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. OmniAb specializes in licensing antibody discovery research technology to pharmaceutical and biotech companies.
OmniAb, Inc. (NASDAQ:OABI) Q3 2025 Earnings Call Transcript
This is the Q3 2025 earnings call transcript for OmniAb, Inc. (NASDAQ:OABI). The content provided is likely a detailed record of the company's financial performance, operational highlights, and future outlook as discussed by management during the call. Investors and analysts would typically review such transcripts for in-depth insights into the company's business.
OmniAb, Inc. (NASDAQ:OABI) Q3 2025 Earnings Call Transcript
This article is an earnings call transcript for OmniAb, Inc. (NASDAQ:OABI) for the third quarter of 2025. It would typically contain discussions on financial performance, future outlook, and Q&A with analysts and management.
EBITDA per share of OmniAb, Inc. – NASDAQ:OABIW
This article provides access to the EBITDA per share data for OmniAb, Inc. (NASDAQ: OABIW) through the TradingView platform. It highlights the availability of financial information, stock market data, and other analytical tools for the company. The content also mentions the various features and services offered by TradingView for market analysis and trading education.
Working capital per share of OmniAb, Inc. – NASDAQ:OABIW
This article provides financial information for OmniAb, Inc. (NASDAQ: OABIW), specifically focusing on its working capital per share, as presented on TradingView. The page indicates that the market is currently closed and provides general financial data and tools available on the platform.
OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026
OmniAb Inc. (NASDAQ: OABI) is expected to build momentum in 2026, driven by projected revenues of $25 million to $30 million. This growth is anticipated from an expanding partner pipeline and the launch of new products like OmniUltra and xPloration. CEO Matthew Foehr highlights the importance of partnerships and the innovative OmniUltra platform, while CFO Kurt Gustafson forecasts 2026 expenses between $80 million and $85 million, with a projected cash balance of $30 million to $35 million.
Free cash flow per share of OmniAb, Inc. – NASDAQ:OABIW
This article focuses on the free cash flow per share of OmniAb, Inc., traded on NASDAQ under the ticker OABIW. It appears to be a page from a financial data platform, providing a direct view of a specific financial metric for the company. The content includes the company's stock market information and indicates where relevant financial data can be found.
OmniAb director Foehr sells $29k in shares By Investing.com
OmniAb director Matthew W. Foehr sold 19,244 shares of common stock for approximately $28,673. Despite this, he also acquired a significant number of shares and restricted stock units, now directly owning over 4.4 million shares and 309,376 RSUs. The company recently reported a decrease in Q4 2025 revenues and a net loss, but analysts maintain a positive outlook and "Strong Buy" consensus, citing growth in active partners and programs.
OmniAb (OABI) chief legal officer Berkman sells $10,663 in stock
OmniAb's Chief Legal Officer, Charles S. Berkman, sold 7,157 shares of common stock for a total of $10,663, while also exercising options for 13,542 shares at $0. This occurred as the stock is down 18% year-to-date and is considered slightly overvalued. Despite recent financial challenges, such as decreased revenues and a net loss, analysts have reiterated Buy ratings, citing growth in partnerships and positive sector developments.
OmniAb director Foehr sells $29k in shares
OmniAb, Inc. Director Matthew W. Foehr sold 19,244 shares of common stock for approximately $28,673 on April 7, 2026. Despite this sale and a year-to-date stock decline, Foehr still directly owns over 4.4 million shares and 309,376 Restricted Stock Units after also acquiring and converting shares. Analysts maintain a "strong buy" consensus on OABI, with several firms reiterating positive outlooks and price targets despite recent revenue declines, based on increasing active partners and programs.
OmniAb CFO Kurt Gustafson sells $10,300 in shares By Investing.com
OmniAb's CFO, Kurt Gustafson, sold 6,913 shares of common stock totaling approximately $10,300, with individual transactions ranging from $1.46 to $1.53 per share. Concurrently, Gustafson exercised options to acquire 13,542 shares at a strike price of $0, increasing his direct ownership to 261,483 shares. Despite a recent revenue decrease and net loss, analysts have maintained positive ratings for OmniAb, viewing the biotech sector favorably and considering recent trial failures as not impacting the company's outlook.
Kurt Gustafson Sells 6,913 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb CFO Kurt Gustafson sold 6,913 shares of OABI stock on April 7th for approximately $10,300 to cover tax withholding obligations from vesting equity awards. Following this sale, Gustafson's stake in the company decreased by 2.58% to 261,483 shares. OmniAb's stock traded down after the announcement, and the company recently missed quarterly earnings and revenue expectations.
OmniAb (NASDAQ:OABI) Insider Sells $10,663.93 in Stock
OmniAb (NASDAQ:OABI) insider Charles Berkman sold 7,157 shares worth $10,663.93 to cover tax withholding on vested awards, reducing his stake by 1.76%. This comes as the company reported a Q1 earnings and revenue miss, exceeding analyst expectations for losses. OmniAb currently holds an average "Hold" rating from analysts with a target price of $4.50.
OmniAb (NASDAQ:OABI) CEO Matthew Foehr Sells 19,244 Shares
OmniAb CEO Matthew Foehr sold 19,244 shares of OABI stock for approximately $28,674 to cover tax obligations, reducing his stake by 0.43%. This sale follows the company reporting a quarterly earnings and revenue miss, causing the stock to trade down 1.9%. Institutional ownership remains high at 72.08%, with a consensus "Hold" rating and a $4.50 target price.
OmniAb CFO Kurt Gustafson sells $10,300 in shares
OmniAb CFO Kurt Gustafson sold 6,913 shares of common stock for approximately $10,300 at a weighted average price of $1.49, while also exercising options to acquire 13,542 shares at a strike price of $0.00. Following these transactions, Gustafson directly owns 261,483 shares. Despite a decrease in Q4 fiscal 2025 revenues and a net loss, analysts from Benchmark, Stifel, Leerink Partners, and Truist Securities have maintained positive ratings, reflecting a cautiously optimistic outlook.
OmniAb CFO Sells Over $10,000 in Shares
OmniAb, Inc. CFO Kurt Gustafson sold 6,913 shares of the company's stock for over $10,000 to cover tax withholding obligations related to equity awards. This transaction represents a 2.58% decrease in his ownership stake but does not necessarily indicate broader concerns about the company's performance, according to the article. Gustafson still directly owns 261,483 shares valued at more than $389,000.
OmniAb (OABI) chief legal officer Berkman sells $10,663 in stock By Investing.com
OmniAb (OABI) Chief Legal Officer Charles S. Berkman sold 7,157 shares of common stock for $10,663, while also exercising options for 13,542 shares at $0. The stock is down 18% year-to-date and 21% over the past year, with InvestingPro analysis suggesting it is slightly overvalued. Despite recent revenue decreases and a net loss, analysts from Benchmark, Stifel, Truist Securities, and Leerink Partners have reiterated Buy or Outperform ratings, maintaining confidence in OmniAb's potential.
OmniAb director Foehr sells $29k in shares By Investing.com
OmniAb director Matthew W. Foehr sold 19,244 shares of common stock for approximately $28,673, at a weighted average price of $1.49 per share. Despite the stock trading above its fair value according to InvestingPro, analysts maintain a strong buy consensus. The company recently reported a decrease in Q4 fiscal 2025 revenues and a net loss, yet several analyst firms reiterated positive outlooks citing growth in active partners and programs.
OmniAb (OABI) CFO vests RSUs, sells shares in tax sell-to-cover
OmniAb, Inc.'s CFO, Kurt A. Gustafson, reported the vesting of 13,542 Restricted Stock Units on April 7, 2026, which converted into common shares. To cover tax withholding obligations, 6,913 shares were sold in a mandatory "sell-to-cover" transaction at a weighted average price of $1.49 per share. Gustafson now directly holds 261,483 shares, a figure that includes a prior transfer of shares to an ex-spouse.
OABI Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of OmniAb Inc (OABI), detailing its revenue streams, profitability margins, and a comparison with competitors. OABI generates revenue primarily from services, with significant contributions from license and milestone, and royalty revenues. The company exhibits negative gross, operating, and net margins, as well as a negative Return on Equity, indicating financial challenges when benchmarked against competitors like ALMU and BKKT.
Leerink reiterates Outperform on OmniAb stock after partner trial fails
Leerink Partners has reiterated an Outperform rating and a $10.00 price target on OmniAb, Inc. despite a Phase 3 trial failure by its partner Immunovant. The firm expects OmniAb to meet its $25 million to $30 million guidance and sees IMVT-1402 as a significant asset for the company, with potential future milestones and royalties. The article also notes recent positive analyst activity and OmniAb's Q4 financial results, where it surpassed EPS expectations despite a revenue decline.
